Pluristem Therapeutics Inc

NASDAQ:PSTI   3:59:50 PM EDT
2.79
-0.06 (-2.10%)
Products, Regulatory

Pluristem Announces DMC Recommendation Following Interim Analysis Of Its Phase III CLI Study

Published: 12/09/2020 09:15 GMT
Pluristem Therapeutics Inc (PSTI) - Pluristem Announces Dmc Recommendation Following Interim Analysis of Its Phase Iii Cli Study.
Dmc Concluded That Cli Study is Unlikely to Meet Primary Endpoint by Time of Final Analysis.
Dmc Noted That Plx-pad Was Well Tolerated, and No Significant Safety Concerns Were Raised During Study.
Following Dmc's Recommendation, Company Decided to Terminate Cli Study.